جست‌وجوی استاد و پژوهشگر

Atılım Güneş Baydinمشاهده پروفایل

استادیار

• Probabilistic Machine Learning
• Generative Modeling
• Probabilistic Programming
• +۴ مورد دیگر

Dr. Atılım Güneş Baydin is an Assistant Professor in Machine Learning at the University of Oxford , where he leads the Oxford AI for Science Lab . He holds dual appointments in the Department of Computer Science and Department of Engineering Science , and is affiliated with Jesus College , Kellogg College , and the European Lab for Learning and Intelligent Systems (ELLIS) . Academic Roles : Departmental Lecturer (Assistant Professor) in Machine Learning, Senior Researcher in Engineering Science Research Groups : Torr Vision Group, Oxford Applied and Theoretical Machine Learning Group (OATML) His research focuses on probabilistic programming , differentiable programming , and generative modeling , with applications in scientific discovery and space missions. He develops methods for large-scale simulator inference and deep learning for space weather , collaborating with NASA , ESA , and Lawrence Berkeley National Lab . Notable Contributions : Co-organized 7+ NeurIPS workshops on ML for Physical Sciences Led the development of PyProb and DiffSharp probabilistic programming frameworks Served on editorial board of ACM Transactions on AI for Science

Amit Paiمشاهده پروفایل

استاد

• Pharmacokinetics
• Clinical Pharmacy
• Pharmacometrics
• +۶ مورد دیگر

Amit Pai is a Professor and Chair of Clinical Pharmacy at the University of Michigan's College of Pharmacy. He also serves as Co-Director of the Pharmacokinetics Core Laboratory and Associate Director of Pharmacomorphomics for the Morphomics Analysis Group. Education: Pharm.D. from University of Texas at Austin and Health Sciences Center in San Antonio Pharmacy Practice Residency at Bassett Healthcare, Cooperstown Infectious Diseases/Pharmacokinetics Fellowship at University of Illinois at Chicago Research Focus: Dr. Pai specializes in optimal drug dose selection for specific populations , particularly obesity-related pharmacokinetic alterations. His work spans antimicrobial dosing , pharmacomorphomics , and therapeutic drug monitoring , integrating CT imaging and radiomics for body composition analysis. Publication Trends: Recent studies emphasize antibiotic pharmacokinetics in obesity , GLP-1 receptor agonist interactions , and radiomic biomarkers for drug dosing. Collaborative works address pediatric antibiotic regimens and precision oncology . Awards & Recognition: 2023 Russell R. Miller Award (ACCP) 2020 ACCP Excellence in Achievement 2019 SIDP Paper of the Year US FDA Regulatory Science Excellence Award Students & Labs: Mentored researchers like Trey Putnam and Indhumathy Subramaniyan . Leads the Pai Laboratory and collaborates with the Morphomics Analysis Group on body composition studies.

Sanjay Anejaمشاهده پروفایل

استادیار

• Artificial Intelligence
• Machine Learning
• Data Science
• +۷ مورد دیگر

Dr. Sanjay Aneja is an Assistant Professor within the Department of Therapeutic Radiology at Yale School of Medicine, with a secondary appointment in Biomedical Informatics & Data Science. He serves as Director of Clinical Informatics and Director of Medical School Clerkship in Therapeutic Radiology, and is Assistant Cancer Center Director for Bioinformatics at Yale Cancer Center. Dr. Aneja's educational background includes: MD from Yale School of Medicine (2013) BA in Applied Mathematics from Columbia University (2009) Residency in Radiation Oncology at Yale-New Haven Hospital Medicine Internship at Memorial Sloan Kettering Cancer Center Postdoctoral Research Fellowship in Machine Learning at the Center for Outcomes Research and Evaluation (CORE) Research Fellowship at the Department of Health and Human Services Dr. Aneja is a physician-scientist whose research focuses on applying machine learning techniques to clinical oncology. His laboratory develops AI-driven solutions that leverage high-dimensional healthcare data to improve patient outcomes. The Aneja Lab's work spans multiple domains from "calculation to clinic," including machine learning algorithm development (metric learning, generalization theory, interpretability techniques, uncertainty quantification) and clinical applications (outcome prediction, disease classification, clinical workflow automation). His research group has established a national consortium of 7 institutions for developing imaging-based biomarkers of cancer outcomes. Analysis of Dr. Aneja's recent publications reveals a strong focus on applying deep learning to medical imaging, particularly for cancer diagnosis and treatment planning. His work addresses critical challenges in medical AI including model robustness against adversarial attacks, interpretability of deep learning models, and generalization across heterogeneous healthcare data. His research spans multiple cancer types including brain metastases, lung cancer, and breast cancer, with growing interest in patient-reported outcomes and clinical trial matching. Dr. Aneja has received significant research funding and recognition including: NIH Career Development Award NSF Research Grant American Cancer Society Research Award Radiation Society of North America (RSNA) Funding SWOG Hope Grant IBM Computing Research Grant As a mentor, Dr. Aneja leads the Aneja Lab, which includes clinicians, computer scientists, mathematicians, and data scientists working collaboratively on interdisciplinary projects. His lab has established collaborations with Amazon for developing AI-driven patient-reported outcome collection and with SWOG for clinical trial matching research. The lab actively seeks postdoctoral associates and students with quantitative backgrounds to contribute to their innovative research at the intersection of machine learning and clinical medicine. The Aneja Lab maintains active research programs in deep learning for imaging-based biomarkers, interpretability methods for deep learning models, metric learning for "digital twins," generalization of deep learning models across healthcare data streams, physician and patient perception of AI, deep learning methods for patient-reported outcome capture, and natural language processing for clinical trial matching. The lab's GitHub repository hosts several open-source projects related to adversarial imaging, capsule networks, and 3D/2D segmentation techniques.

Peter van der Voortمشاهده پروفایل

استاد

• Health Care Management
• Innovation in Healthcare
• Quality Management
• +۵ مورد دیگر

Peter van der Voort is a Full Professor at TIAS School for Business and Society and University of Groningen , focusing on Health Care Management . He serves as Academic Director of the Executive Master Health Administration (MHA) program and leads research within the TIAS Health cluster. His background as a physician and internist-intensivist at AMC and OLVG informs his expertise in Intensive Care Medicine and clinical leadership. Medical Degree, VU Medical Center Master in Epidemiology, 2006 His research bridges clinical practice with organizational strategy, emphasizing quality management in healthcare systems. Recent work explores: Metabolic factors in respiratory failure (leptin, obesity) Antimicrobial resistance and decolonization Telemedicine and digital transformation Precision dosing in ICU pharmacology Organizational governance in critical care He has co-authored 15+ peer-reviewed articles (2020-2023) on topics spanning: COVID-19 pathophysiology Glucose prediction models Respiratory therapy guidelines Advanced practice provider roles Antibiotic stewardship Healthcare network governance Peter's leadership extends to: Former Head of Adult Intensive Care, University Medical Center Groningen (UMCG) Founding director of Stichting Venticare (telemedicine initiatives) Former Senator for D66, shaping healthcare policy Quality improvement committee leadership

Michael Watersمشاهده پروفایل

استادیار

• Radiation Oncology
• Thoracic Oncology
• Gastrointestinal Oncology
• +۷ مورد دیگر

Michael Waters, MD, PhD is an Assistant Professor of Radiation Oncology at Washington University School of Medicine in St. Louis, with clinical specialization in Thoracic and Gastrointestinal radiation oncology. His work integrates advanced radiation techniques including Stereotactic Body Radiotherapy (SBRT) and Gamma Knife radiosurgery with cutting-edge computational approaches. Dr. Waters' research focuses on applying deep learning, machine learning, and genomics to radiation oncology challenges. His work spans multiple cancer types including lung, pancreatic, prostate, and breast cancers, with particular emphasis on improving treatment precision through adaptive radiotherapy and AI-driven decision support. Current projects include developing generative AI tools for gene expression analysis (GAiN) and implementing large language models to streamline clinical workflows and insurance appeals. His publication record shows consistent productivity with 35 research outputs since 2015, accelerating to 10 publications in 2024-2025. Recent work demonstrates growing influence in AI applications for radiation oncology , with studies on CT-based adaptive therapy for prostate cancer, MR-guided SBRT for pancreatic tumors, and ethical considerations for AI in clinical trial communication. His research has been presented at major conferences including ASTRO, ASCO, and AACR. Dr. Waters completed his MD/PhD at Virginia Commonwealth University (2019), residency in Radiation Oncology at Washington University (2024), and maintains active roles at Siteman Cancer Center and the Institute of Clinical and Translational Sciences (ICTS). His work bridges clinical radiation oncology with computational biology, creating novel approaches to personalize cancer treatment through data-driven methodologies.

• Clinical Cancer Epidemiology
• Precision Oncology
• Artificial Intelligence Safety and Ethics
• +۳ مورد دیگر

Ashley Hopkins is an Associate Professor at the College of Medicine and Public Health , Flinders University. As leader of the Clinical Cancer Epidemiology Lab and a National Breast Cancer Foundation of Australia Postdoctoral Fellow, they bridge precision oncology with artificial intelligence ethics research. Flinders Health and Medical Research Institute Precision Medicines Group Flinders Centre for Innovation in Cancer Research Interests focus on clinical cancer epidemiology and pharmacometric modeling to create actionable prediction strategies for advanced cancer patients. Their work spans: Clinical Prediction Models Big Data Analysis from pharmaceutical trials AI Safety & Ethics Immunotherapy and Targeted Therapy Evaluation Breast/Lung/Colorectal Cancer Research Health Disinformation Mitigation Scientific Awards include: NHMRC Investigator (2022-2026) SA Young Investigator Tall Poppy (2021) Certara New Investigator Award (2020) Vice-Chancellor’s Award for ECRs (2019) Publications highlight trends in: AI application in oncology communication Ethical implications of autonomous AI in medicine Hyperprogressive disease analysis in hepatocellular carcinoma Reliability of AI chatbots for cancer information Supervision Opportunities exist for PhD/Honours students with backgrounds in pharmacy, medical sciences, or biostatistics interested in precision oncology, clinical epidemiology, or ethical AI implementation.

• Rheumatology
• Systemic Lupus Erythematosus
• Autoimmunity
• +۵ مورد دیگر

Roberto Caricchio, MD is a Professor and holds the Myles J. McDonough Chair in Rheumatology at UMass Chan Medical School. He serves in multiple capacities across the institution, including in the Department of Medicine (Division of Rheumatology) at the T.H. Chan School of Medicine, and in several departments within the Morningside Graduate School of Biomedical Sciences including Immunology and Microbiology Program, Interdisciplinary Graduate Program, MD/PhD Program, and Translational Science. Dr. Caricchio received his MD from Catholic University in Rome, Italy. His extensive academic career has focused on rheumatology and autoimmune diseases, particularly Systemic Lupus Erythematosus (SLE). Dr. Caricchio's research primarily centers on the immunopathogenesis of autoimmune diseases, with special emphasis on Systemic Lupus Erythematosus. His work explores the mechanisms of cytokine storms, the role of bacterial infections in triggering autoimmunity, and the immunological basis of lupus nephritis. Recent research has expanded to include the intersection of autoimmune diseases and COVID-19, examining how viral infections can exacerbate autoimmune conditions and studying vaccine responses in immunosuppressed patients. His publication record demonstrates a strong focus on translational research, with numerous studies bridging basic immunological mechanisms to clinical applications. Recent work has particularly emphasized the role of bacterial biofilms, curli/DNA complexes, and endogenous retroviruses in lupus pathogenesis, as well as innovative therapeutic approaches including CAR T cell therapy for autoimmune conditions. Dr. Caricchio has collaborated extensively with researchers across multiple institutions, contributing to significant advancements in understanding autoimmune mechanisms and developing novel treatment approaches for lupus and related conditions. His work has been supported by various research grants, though specific funding sources are not detailed in the provided information. He has mentored numerous students and researchers through his roles in graduate programs, though specific names of advisees are not provided in the current data. Dr. Caricchio's laboratory and research team focus on understanding the immunological mechanisms underlying lupus and other autoimmune diseases, with particular attention to the role of bacterial triggers, cytokine networks, and sex differences in disease manifestation.

• Medical Oncology
• Pharmacology
• Palliative Care
• +۱ مورد دیگر

Annemieke van der Padt - Pruijsten is a researcher in the Department of Medical Oncology at Erasmus MC, Erasmus University Rotterdam. Her work focuses on advancing cancer treatment through precision dosing strategies and pharmacokinetic studies. Research interests include: Model-informed precision dosing for hormonal therapies in breast cancer Pharmacokinetic interactions of anticancer drugs with common medications Development and implementation of palliative care pathways for advanced cancer patients Recent publications highlight her contributions to optimizing tamoxifen therapy, understanding drug transporter interactions (OCT2/MATE1), and evaluating palliative care quality from bereaved relatives' perspectives.

Nikolai J. Mickeviciusمشاهده پروفایل

استادیار

• Magnetic Resonance Imaging
• Biophysics
• Medical Imaging
• +۳ مورد دیگر

Nikolai J. Mickevicius, PhD, is an Assistant Professor in the Department of Biophysics at the Medical College of Wisconsin (MCW). He holds a PhD in Biophysics from MCW (2018) and a BS in Biomedical Engineering from the Milwaukee School of Engineering (2013). Prior to his faculty position at MCW, he served as a research scientist in the Department of Radiation Oncology at MCW and completed a Bentson Translational Research Fellowship at the University of Wisconsin–Madison's Department of Human Oncology. His current work focuses on advancing MRI technologies for clinical applications. Education: PhD in Biophysics, Medical College of Wisconsin, 2018 BS in Biomedical Engineering, Milwaukee School of Engineering, 2013 Research Focus: Dr. Mickevicius' laboratory develops cutting-edge MRI pulse sequences and reconstruction algorithms to enhance diagnostic information within clinically feasible scan times. His work emphasizes applications in radiation therapy guidance, real-time motion monitoring, and multi-spectral imaging. Key Research Areas: MRI acceleration techniques Deep learning for image recovery MRI-guided radiation therapy Multi-orientation imaging Publications Overview: His recent work includes advancements in simultaneous multi-orientation MRI, deep learning-driven image reconstruction, and real-time motion management systems for therapeutic applications. These innovations aim to improve diagnostic accuracy and treatment precision in oncology settings. Labs/Teams: He leads a research group focused on translational MRI technologies at MCW, collaborating with oncology and radiology teams to advance clinical imaging solutions.

Klaus Tapio Olkkolaمشاهده پروفایل

استاد

• Anesthesiology
• Intensive Care
• Pharmacokinetics
• +۴ مورد دیگر

Professor Klaus Tapio Olkkola is a distinguished academic and clinician at the University of Helsinki, serving as Professor of Anesthesiology and Intensive Care and Director of Clinicum. He holds appointments in the Faculty of Medicine, Department of Diagnostics and Therapeutics, and is actively involved in clinical practice at Helsinki University Central Hospital. His leadership extends to supervising doctoral programs in Drug Research and Clinical Research. Bachelor of Medicine (MB), University of Helsinki, 1979 Licentiate in Medicine (MD), University of Helsinki, 1983 Doctor of Medical Science (MScD), University of Helsinki, 1985 Docent in Pharmacology, University of Helsinki, 1991 Docent in Anesthesiology, University of Helsinki, 1995 Special competence in medical education, Finnish Medical Association, 2010 Professor Olkkola's research spans anesthesiology, intensive care, pharmacokinetics, and pharmacodynamics , with particular focus on drug interactions, pain management, and emergency medicine. His work examines how cytochrome P-450 isozymes affect intravenous anesthetics, pharmacogenomics in anesthesia dosing, and management of pain in children. His recent studies have explored ketamine analgo-sedation, propofol requirements influenced by genetics, and physiologically based pharmacokinetic modeling of drug interactions. His scientific contributions have been recognized through multiple awards including Young Scientist's Awards from the Finnish Society of Anaesthesiologists and Scandinavian Society of Anaesthesiologists, the Acta Award, and recognition as a Corresponding Member of the German Society of Anaesthesiology and Intensive Care Medicine. He has served on editorial boards for prestigious journals including the European Journal of Anaesthesiology and Current Opinion in Anaesthesiology. Professor Olkkola has mentored over 20 doctoral students whose work spans diverse areas of anesthesiology and pharmacology. His research has been supported by numerous grants from the Alexander von Humboldt Foundation, Finnish foundations, and pharmaceutical industry. He actively participates in guideline development for major medical societies including the Scandinavian Society of Anaesthesiology and Intensive Care Medicine.

• Cardiovascular Disease
• Heart Failure
• Clinical Trials
• +۳ مورد دیگر

Dr. Li Shen is an Honorary Research Fellow at the University of Glasgow's School of Cardiovascular & Metabolic Health, specializing in cardiovascular research with a focus on heart failure mechanisms, clinical outcomes, and therapeutic interventions. His work integrates large clinical trial data (e.g., PARADIGM-HF, PARAGON-HF) to explore treatment efficacy across patient subgroups, including those with diabetes, renal impairment, and comorbidities like cancer. Research interests include prognostic modeling for sudden/pump-failure death, drug safety (e.g., beta-blockers, sacubitril/valsartan), and disparities in heart failure outcomes based on race, gender, and socioeconomic factors. His studies often analyze biomarkers (e.g., prognostic nutritional index) and comorbidities (e.g., diabetes, frailty) to refine patient stratification and treatment strategies. Recent articles highlight advancements in understanding heart failure subtypes (HFrEF/HFpEF), drug interactions in polypharmacy, and the impact of therapies like dapagliflozin in diabetic populations. Collaborations with global research networks (e.g., Swedish Heart Failure Registry) enhance the generalizability of findings. Key contributions include validating predictive models for mortality/morbidity and investigating the declining incidence of sudden cardiac death in heart failure populations over time. This work informs precision medicine approaches and clinical guidelines for optimized heart failure management.

• Radiation Oncology
• Cancer Biology
• Brain Tumors
• +۵ مورد دیگر

Aram Modrek is an Assistant Professor of Radiation Oncology and Cancer Biology in the Department of Radiation Oncology at the Keck School of Medicine of the University of Southern California. He serves as Culture and Engagement Champion for the Department and is an active member of the USC Norris Comprehensive Cancer Center, Epigenetic Regulation in Cancer Program, and USC Brain Tumor Center. Dr. Modrek's research centers on DNA damage-induced genomic alterations and their impact on gene regulation in brain tumors, with particular focus on treatment resistance mechanisms. His lab employs cutting-edge genomic and transcriptomic approaches to investigate how cancer cells adapt to therapy, aiming to develop strategies that disrupt these adaptive processes. Key research areas include radiation biology, glioblastoma pathogenesis, epigenetic regulation, and molecular mechanisms of therapeutic resistance. His publication record demonstrates consistent productivity with 15+ recent articles spanning radiation oncology, cancer biology, and neuro-oncology. Research themes prominently feature brain tumor genomics, DNA damage response pathways, and translational applications of molecular findings. Recent work includes investigations into platelet transcriptomes in cancer, radiation resistance mechanisms in glioblastoma, and novel therapeutic targets like PDPN and GPR133. No scientific awards were explicitly mentioned in the source material. Dr. Modrek leads the Modrek Lab with support from external funding sources, though specific grants aren't detailed in the provided text. His work bridges basic science and clinical applications, evidenced by publications spanning molecular mechanisms to clinical decision support tools. The lab operates within USC's robust cancer research infrastructure, collaborating across multiple centers including the Brain Tumor Center. The Modrek Lab functions within the Department of Radiation Oncology at USC, actively participating in the university's cancer research ecosystem through the Norris Comprehensive Cancer Center and specialized programs focused on brain tumors and epigenetic regulation.

• Environmental Health
• Toxicology
• Chemical Biology
• +۳ مورد دیگر

Xiaojing Li is a Postdoctoral Researcher in the Department of Precision Environmental Health, focusing on environmental health and toxicology. She leads the 'Precision Environmental Health' project (2024–2027), funded by the Natural Environment Research Council. Her work addresses chemical mixtures, Daphnia biology, and molecular mechanisms in ecotoxicology. Research interests include chemical toxicity, environmental sex determination, and high-throughput testing methodologies. Recent studies explore bioactivity profiling of pollutants, metabolomics in toxicity assessment, and modernizing chemical risk evaluation. She contributes to global sustainable development goals related to clean water and responsible consumption. Key collaborations involve institutions globally, with emphasis on aquatic toxicology and environmental regulation. Her research bridges molecular mechanisms with ecological impacts, aiming to inform policy and chemical safety practices.

• Data Warehousing
• Clinical Data Quality
• Privacy-Preserving Record Linkage
• +۵ مورد دیگر

Douglas Bell is a Professor-in-Residence in both Medicine and Computational Medicine at the David Geffen School of Medicine, University of California Los Angeles (UCLA) . With a career spanning over 35 years, he is a leading figure in biomedical informatics, focusing on clinical data quality, patient record linkage, and machine learning applications in healthcare. Education: B.A. in Biochemistry and Computer Science, Case Western Reserve University (1985) M.D., Harvard Medical School (1990) Medical Informatics Fellowship, Harvard-MIT Division of Health Science and Technology (1994) Ph.D. in Health Services, UCLA (2000) His research explores data warehousing , privacy-preserving record linkage , and machine learning in medical diagnosis . He leads UCLA's participation in the National COVID Cohort Collaboration (N3C) and 4CE Consortium , analyzing global EHR data for pandemic response. Recent work includes developing simulation models for chronic kidney disease prediction and improving race-ethnicity data completeness in health records. Key areas in his work include: International EHR data harmonization Reducing alert fatigue in clinical decision support Precision phenotyping for research cohorts Mentoring clinical informatics fellows Addressing health disparities in diabetes care Scientific honors include: Best Poster Award, AMIA (2016) ACMI Fellowship (2007) HHMI/NIH Research Scholar (1988) Phi Beta Kappa (1984) He has trained over 100 clinical informatics fellows and currently serves as Leader of the Informatics Program at UCLA CTSI , advancing biomedical discovery through data science innovation.

• Cancer Genetics
• Colorectal Cancer
• Breast Cancer
• +۹ مورد دیگر

Professor Rodney Scott is a leading geneticist at the School of Biomedical Sciences and Pharmacy , University of Newcastle, Australia. He co-directs the Centre for Bioinformatics, Biomarker Discovery and Information-Based Medicine , pioneering interdisciplinary research linking bioinformatics with clinical practice to advance personalized medicine. His career spans over 20 years in hereditary cancer research, with global recognition in breast cancer , colorectal cancer , and Lynch syndrome genetics. Education : Privat Dozent (German DSc equivalent), University of Basel; PhD and BSc (Honours), University of Western Australia. Scott’s research focuses on the genetic basis of malignancy , including modifier genes in disease penetrance, epigenetics in multiple sclerosis , and DNA repair mechanisms . His work bridges clinical genetics , bioinformatics , and pharmacogenomics , with recent studies on epigenetic signatures for disease progression and machine learning applications in genomic data analysis. His 15 most recent articles highlight trends in genomic risk modeling , epigenetics , environmental-cancer interactions , and pharmacogenomic testing . Key areas include endometrial and colorectal cancer susceptibility loci , DPYD-guided chemotherapy , and multi-omics approaches to multiple sclerosis and schizophrenia . Scientific Awards : Fellow of the Royal Society of NSW (2017); Honorary PhD from Pomeranian Academy of Medicine (2017); FRCPath (2005); Fellow of Royal College of Pathologists of Australasia (2011). Scott has supervised numerous PhD students and contributes to national committees on genetic services and bioethics . He collaborates extensively with the Hunter Medical Research Institute and international institutions, integrating genomic and clinical data for translational impact.